ESTRO 2025 - Abstract Book

S1776

Clinical – Upper GI

ESTRO 2025

Keywords: Gastric cancer, phase 2, chemoradiotherapy

References: Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018 Sep 10;18(1):877.

1632

Digital Poster Association between liver volume reduction and liver function decline after radiotherapy for hepatocellular carcinoma Saori Tatsuno 1 , Hiroshi Doi 1 , Masakazu Otsuka 2 , Kenji Matsumoto 2 , Tomoko Hyodo 3 , Kazuomi Ueshima 4 , Masatoshi Kudo 4 , Kazunari Ishii 3 , Yukinori Matsuo 1 1 1. Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 2 2. Department of Radiology Service, Kindai University Hospital, Osaka-Sayama, Japan. 3 3. Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 4 4. Department of Gastroenterology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan Purpose/Objective: Radiotherapy for hepatocellular carcinoma (HCC) has been used with curative intent and has been reported to achieve excellent local control [1]. However, a decline of liver function after definitive radiotherapy remains a clinically significant issue [2]. The aim of this study was to assess the association between liver volume reduction and liver function decline after radiotherapy in patients with HCC treated with radiotherapy. Material/Methods: Ten patients with HCC who received radiotherapy with a biologically effective dose (BED10) > 50 Gy between September 2021 and January 2023 were retrospectively analyzed in this study. Liver function, which was quantified by Child-Pugh and albumin-bilirubin (ALBI) scores, was assessed before and after radiotherapy. Volumetric assessment of the liver was performed using SYNAPSE VINCENT® (Fujifilm Medical Co., Ltd., Tokyo, Japan) in serial CT or MRI images before and up to 12 months after treatment. The change in liver volume, ALBI score, and Child Pugh score was defined as a ratio of the worst value to the pre-radiotherapy value. The statistical correlation between liver volume reduction and functional scores was determined using the Spearman rank correlation coefficient. Results: The median age was 76.5 (range, 58-89) years. Five and five patients received radiotherapy with 40 Gy in 4 fractions and 45 Gy in 15 fractions, respectively. The coincidence of liver volume between CT and MRI images was validated with the differences of < 4% using CT and MRI images which were performed on the same day before radiotherapy in five patients. The pre-radiotherapy ALBI score was grade 1 and 2 in one and nine patients, respectively. Pre radiotherapy Child-Pugh score was grade A and grade B in four and six patients, respectively. The median pre radiotherapy liver volume was 1196 (range, 786-2542) cc. A decrease in liver volume and decline of liver function were observed after radiotherapy compared with before radiotherapy in all eligible patients. The median time to the worst value was 10.5 (3-12), 12 (6-12), and 12 (6-12) months in liver volume, ALBI score, and Child-Pugh score, respectively. The mean change (standard deviation) in liver volume, ALBI score, and Child-Pugh score were 0.79 (0.13), 0.72 (0.27), and 1.26 (0.18), respectively. Significant correlations were observed between the reduction of liver